Investor’s Delight: Ginkgo Bioworks Holdings Inc (DNA) Closes Strong at 7.93, Up 3.39

In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.

The closing price of Ginkgo Bioworks Holdings Inc (NYSE: DNA) was $7.93 for the day, up 3.39% from the previous closing price of $7.67. In other words, the price has increased by $3.39 from its previous closing price. On the day, 0.82 million shares were traded.

Ratios:

Our analysis of DNA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.88 and its Current Ratio is at 4.88. In the meantime, Its Debt-to-Equity ratio is 0.67 whereas as Long-Term Debt/Eq ratio is at 0.67.

Raymond James Downgraded its Outperform to Mkt Perform on November 14, 2023, whereas the target price for the stock was revised from $3.50 to $2.50.

Insider Transactions:

Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 16 ’25 when Che Austin bought 99 shares for $7.72 per share.

Che Austin bought 99 shares of DNA for $765 on May 15 ’25. On May 14 ’25, another insider, Che Austin, who serves as the Officer of the company, bought 99 shares for $8.01 each.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 1.96 while its Price-to-Book (P/B) ratio in mrq is 0.63.

Stock Price History:

Over the past 52 weeks, DNA has reached a high of $34.78, while it has fallen to a 52-week low of $5.00. The 50-Day Moving Average of the stock is 10.33%, while the 200-Day Moving Average is calculated to be -10.31%.

Shares Statistics:

A total of 43.08M shares are outstanding, with a floating share count of 37.41M. Insiders hold about 32.63% of the company’s shares, while institutions hold 57.94% stake in the company.

Earnings Estimates

The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.

Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0.

Revenue Estimates

It is expected that $90B in revenue will be generated in the current quarter, according to 5 analysts. It ranges from a high estimate of $44M to a low estimate of $38.19M. As of the current estimate, Ginkgo Bioworks Holdings Inc’s year-ago sales were $56.21MFor the next quarter, 5 analysts are estimating revenue of $43.79M. There is a high estimate of $45.85M for the next quarter, whereas the lowest estimate is $41.3M.

A total of 6 analysts have provided revenue estimates for DNA’s current fiscal year. The highest revenue estimate was $180M, while the lowest revenue estimate was $170.97M, resulting in an average revenue estimate of $175.51M. In the same quarter a year ago, actual revenue was $227.04MBased on 6 analysts’ estimates, the company’s revenue will be $197.05M in the next fiscal year. The high estimate is $220.01M and the low estimate is $171.56M.

DWinneX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.